drugset / Trial / NCT05304351
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older
Timeline
- Start
- 2022-02-02
- Primary completion
- 2026-06-30
- Completion
- 2032-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | Intramuscular |
| Subject | amezosvatein | Vaccine | — | Intramuscular |